bisoprolol has been researched along with Brugada Syndrome in 1 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Brugada Syndrome: An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Strikingly, arrhythmia events were more frequently detected in BrS-hiPSC-CMs." | 1.72 | A Preclinical Study on Brugada Syndrome with a CACNB2 Variant Using Human Cardiomyocytes from Induced Pluripotent Stem Cells. ( Akin, I; Albers, S; Cyganek, L; Diecke, S; Dinkel, H; Duru, F; El-Battrawy, I; Hohn, A; Huang, M; Janssen, JWG; Kleinsorge, M; Lan, H; Lang, S; Li, X; Li, Y; Liao, Z; Maywald, L; Müller, J; Qiao, L; Rose, L; Saguner, A; Schimanski, T; Swamy, N; Xi, Y; Xu, Q; Yang, Z; Zhang, F; Zhao, Z; Zhong, R; Zhou, X, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhong, R | 1 |
| Schimanski, T | 1 |
| Zhang, F | 1 |
| Lan, H | 1 |
| Hohn, A | 1 |
| Xu, Q | 1 |
| Huang, M | 1 |
| Liao, Z | 1 |
| Qiao, L | 1 |
| Yang, Z | 1 |
| Li, Y | 1 |
| Zhao, Z | 1 |
| Li, X | 1 |
| Rose, L | 1 |
| Albers, S | 1 |
| Maywald, L | 1 |
| Müller, J | 1 |
| Dinkel, H | 1 |
| Saguner, A | 1 |
| Janssen, JWG | 1 |
| Swamy, N | 1 |
| Xi, Y | 1 |
| Lang, S | 1 |
| Kleinsorge, M | 1 |
| Duru, F | 1 |
| Zhou, X | 1 |
| Diecke, S | 1 |
| Cyganek, L | 1 |
| Akin, I | 1 |
| El-Battrawy, I | 1 |
1 other study available for bisoprolol and Brugada Syndrome
| Article | Year |
|---|---|
A Preclinical Study on Brugada Syndrome with a CACNB2 Variant Using Human Cardiomyocytes from Induced Pluripotent Stem Cells.
Topics: Action Potentials; Arrhythmias, Cardiac; Bisoprolol; Brugada Syndrome; Calcium Channels, L-Type; Hum | 2022 |